Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 31, 2011. The filing addresses Item 5.02 regarding the appointment of a certain officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation.
Material Changes
The Board of Directors appointed Philip MacNeill as the Company's Controller and Principal Accounting Officer, effective September 8, 2011. Mr. MacNeill had previously joined the Company in January 2011 as Controller. He brings over 30 years of experience in finance and accounting, primarily in the government contracting industry.
Management Commentary and Compensation
- Compensation: Mr. MacNeill's annual base salary is set at $175,000.
- Incentives: He is eligible for an annual bonus and awards under the Company's 2007 Long-Term Incentive Compensation Plan.
- Background: Prior experience includes roles at 3e Technologies International, Inc., BAE Systems plc, Presearch Incorporated, JHM Research and Development, Inc., and The Mitre Corporation.
Investor Verification Checklist
- Verify the effective date of the appointment (September 8, 2011).
- Confirm the total compensation package including potential bonus and long-term incentive structures.
- Note the discrepancy between the requested company name (Altimmune, Inc.) and the filing registrant (PharmAthene, Inc.).
- Review the 2007 Long-Term Incentive Compensation Plan for details on award eligibility.